HK1212773A1 - 用於腎損傷和腎衰竭的診斷及預後的方法和組合物 - Google Patents

用於腎損傷和腎衰竭的診斷及預後的方法和組合物

Info

Publication number
HK1212773A1
HK1212773A1 HK16100658.5A HK16100658A HK1212773A1 HK 1212773 A1 HK1212773 A1 HK 1212773A1 HK 16100658 A HK16100658 A HK 16100658A HK 1212773 A1 HK1212773 A1 HK 1212773A1
Authority
HK
Hong Kong
Prior art keywords
renal
prognosis
diagnosis
compositions
methods
Prior art date
Application number
HK16100658.5A
Other languages
English (en)
Inventor
．安德伯格
．格雷
．麥克弗森
．中村
‧坎普夫
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of HK1212773A1 publication Critical patent/HK1212773A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
HK16100658.5A 2013-01-17 2016-01-21 用於腎損傷和腎衰竭的診斷及預後的方法和組合物 HK1212773A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361753723P 2013-01-17 2013-01-17
PCT/US2014/011830 WO2014113558A1 (en) 2013-01-17 2014-01-16 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
HK1212773A1 true HK1212773A1 (zh) 2016-06-17

Family

ID=51210059

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16100658.5A HK1212773A1 (zh) 2013-01-17 2016-01-21 用於腎損傷和腎衰竭的診斷及預後的方法和組合物
HK18112991.4A HK1253858A1 (zh) 2013-01-17 2018-10-11 用於腎損傷和腎衰竭的診斷及預後的方法和組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18112991.4A HK1253858A1 (zh) 2013-01-17 2018-10-11 用於腎損傷和腎衰竭的診斷及預後的方法和組合物

Country Status (12)

Country Link
US (4) US9360488B2 (zh)
EP (4) EP2946211B1 (zh)
JP (2) JP6681195B2 (zh)
CN (2) CN105074466B (zh)
AU (2) AU2014207509B2 (zh)
CA (2) CA2898581C (zh)
ES (2) ES2681955T3 (zh)
HK (2) HK1212773A1 (zh)
PL (1) PL2946211T3 (zh)
PT (1) PT2946211T (zh)
TR (1) TR201807542T4 (zh)
WO (1) WO2014113558A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104399089B (zh) 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
CN105051542A (zh) * 2012-10-31 2015-11-11 阿斯图德医疗有限公司 定量的侧向流测定法
AU2014207509B2 (en) 2013-01-17 2019-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105102980B (zh) 2013-02-26 2017-11-03 阿斯图特医药公司 具有试条保持件的横向流动测定法
CN105917229B (zh) * 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
US9928347B2 (en) * 2014-04-02 2018-03-27 University Of Louisville Research Foundation, Inc. Computer aided diagnostic system for classifying kidneys
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10542923B2 (en) 2015-04-15 2020-01-28 The Johns Hopkins University System and urine sensing devices for and method of monitoring kidney function
US11612359B2 (en) * 2016-04-06 2023-03-28 Cardiac Pacemakers, Inc. Renal dysfunction risk stratification
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
WO2018081578A1 (en) * 2016-10-28 2018-05-03 Astute Medical, Inc. Use of antibodies to timp-2 for the improvement of renal function
CN110431422A (zh) * 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
JP7315466B2 (ja) 2017-04-05 2023-07-26 アスチュート メディカル，インコーポレイテッド 生体試料中において改善した性能を有する、ｔｉｍｐ２に関するアッセイ
US11669970B2 (en) * 2017-04-07 2023-06-06 Children's National Medical Center System, apparatus, and method for detection of ureteropelvic junction obstruction
IT201800005070A1 (it) * 2018-05-04 2019-11-04 Metodo per la previsione dell’insorgenza di danno renale acuto in un gruppo di pazienti
CA3101470A1 (en) 2018-05-24 2019-11-28 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
WO2021018774A1 (en) * 2019-07-26 2021-02-04 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Ergothioneine, s-methyl-ergothioneine, and uses thereof
US20220283172A1 (en) * 2019-08-07 2022-09-08 The Johns Hopkins University Reduce discard of kidneys for transplanation after brain death
CN112348166A (zh) * 2020-09-25 2021-02-09 四川大学华西医院 基于血清肌酐和胱抑素c预测肌力下降筛查肌少症的方法
CN112798789A (zh) * 2020-12-08 2021-05-14 彭志勇 一种用于重症患者aki早期诊断的方法
CN113436675B (zh) * 2021-06-24 2024-03-26 广州医科大学附属第一医院（广州呼吸中心） 基于血液滤过方式清除体外循环突触核蛋白的方法
CN115458158B (zh) * 2022-09-23 2023-09-15 深圳大学 一种针对脓毒症患者的急性肾损伤预测系统

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1429031A1 (ru) 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Способ дифференциальной диагностики гломерулонефрита и пиелонефрита
CA1330302C (en) 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
JPH06506688A (ja) 1991-04-10 1994-07-28 バイオサイト・ダイアグノスティックス・インコーポレイテッド クロストークインヒビターおよびその使用
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
SK285461B6 (sk) 1996-05-24 2007-02-01 Biogen Idec Ma Inc. Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid
US5753455A (en) 1996-09-03 1998-05-19 Bayer Corporation Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU7549498A (en) 1997-06-03 1998-12-21 Protegene Inc. Human proteins having transmembrane domains and dnas encoding these prot eins
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
EP1151101A4 (en) 1998-12-18 2002-10-09 Human Genome Sciences Inc PROSTACYCLINE STIMULANT FACTOR-2
MXPA01006404A (es) 1998-12-21 2003-06-06 Univ Monash Deteccion y tratamiento de enfermedad renal.
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20040023293A1 (en) * 1999-09-27 2004-02-05 Kreimer David I. Biochips for characterizing biological processes
RU2180965C1 (ru) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Способ дифференциальной диагностики заболеваний почек
AU2002216273A1 (en) 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20040126767A1 (en) 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en) 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
HUP0400659A3 (en) 2001-07-24 2005-06-28 Zhu Zhou Woodbridge Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
JP2003081838A (ja) 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
GB0130557D0 (en) 2001-12-20 2002-02-06 Serono Internat S A Proteins
AU2003219275B2 (en) 2002-03-07 2008-01-24 Cambridge Enterprise Ltd SCD fingerprints
WO2003081201A2 (en) 2002-03-21 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7138229B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
AU2003281287A1 (en) 2002-07-04 2004-01-23 Oxford Glycosciences (Uk) Ltd Toxicity markers
US6941172B2 (en) 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
WO2004053074A2 (en) 2002-12-06 2004-06-24 Science And Technology Corporation @ Unm Outcome prediction and risk classification in childhood leukemia
AU2003302340B8 (en) 2002-12-24 2008-09-11 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CN1791797A (zh) 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US7560244B2 (en) 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
WO2005017203A2 (en) 2003-07-11 2005-02-24 Yale University Systems and methods for diagnosing and treating psychological and behavioral conditions
ES2481672T3 (es) 2003-07-17 2014-07-31 Pacific Edge Limited Marcadores para la detección del cáncer gástrico
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
CA2560200A1 (en) 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
WO2005103281A2 (en) 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2872579B1 (fr) 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
US7588892B2 (en) 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
WO2006008661A2 (en) 2004-07-19 2006-01-26 Neurochem (International) Limited Diagnostic methods of multiple organ amyloidosis
DE602005014778D1 (de) 2004-07-28 2009-07-16 Hoffmann La Roche Timp-2 als ziel/marker des versagens von beta-zellen
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
FI20050011A (fi) 2005-01-05 2006-07-06 Jurilab Ltd Oy Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi
WO2006083986A2 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services Biomarkers for tissue status
ITVI20050059A1 (it) 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
EP2604703B1 (en) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Methods for evaluating graft survival in a solid organ transplant recipient
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
JP2008538238A (ja) 2005-03-31 2008-10-16 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 神経精神障害を診断および処置するための組成物および方法
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
DE602006017534D1 (de) 2005-04-18 2010-11-25 Mitomics Inc Mitochondriale mutationen und umlagerungen als diagnostisches werkzeug zum nachweis von sonneneinstrahlung, prostatakrebs und anderen krebserkrankungen
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7833732B2 (en) * 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
EP1931990A4 (en) 2005-10-03 2010-03-10 Biosite Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND / OR FORECASTING IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
US20080090304A1 (en) 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US10716749B2 (en) 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
AU2006336091C1 (en) 2006-01-20 2014-01-16 Mosaiques Diagnostics And Therapeutics Ag Method and markers for the diagnosis of renal diseases
WO2007106781A2 (en) 2006-03-10 2007-09-20 University Of Rochester Ecg-based differentiation of lqt1 and lqt2 mutation
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
WO2007124331A2 (en) 2006-04-19 2007-11-01 Virginia Commonwealth University Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
CA2592372A1 (en) 2006-06-20 2007-12-20 Institut De Cardiologie De Montreal Angiopoietin-like 2 as a biomarker of vascular endothelial cell abnormal function and senescence
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
WO2008005375A2 (en) 2006-06-30 2008-01-10 Merck & Co., Inc. Kidney toxicity biomarkers
EP2049713A4 (en) 2006-07-21 2010-06-16 Univ Alberta TISSUE REJECTION
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
EP2095107B1 (en) 2006-11-14 2014-07-02 Alere San Diego, Inc. Methods for risk assignment
CA2665489C (en) 2006-12-08 2017-08-29 The Children's Hospital Of Philadelphia Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
CA2671298C (en) 2007-01-25 2020-07-28 F. Hoffmann-La Roche Ag Use of igfbp-7 in the assessment of heart failure
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
CN101679525B (zh) 2007-03-26 2013-06-19 诺瓦提斯公司 用于监测肾功能的预测性的肾安全性生物标志物和生物标志物标签
CA2682538A1 (en) 2007-04-10 2008-10-16 Integragen Human diabetes susceptibility tnfrsf10b gene
US8080394B2 (en) 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
US9091695B2 (en) 2007-06-01 2015-07-28 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
US20100184110A1 (en) 2007-06-06 2010-07-22 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
US20090047689A1 (en) 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
EP2637020A3 (en) 2007-06-29 2014-01-08 Correlogic Systems Inc. Predictive markers for ovarian cancer
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
WO2009039421A1 (en) 2007-09-20 2009-03-26 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
WO2009038742A2 (en) 2007-09-20 2009-03-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
US8003333B2 (en) 2007-09-28 2011-08-23 Mayo Foundation For Medical Education And Research Serum biomarkers for early detection of acute cellular rejection
ES2475990T5 (es) 2007-11-15 2017-07-06 Bioporto Diagnostics A/S Uso diagnóstico de formas moleculares individuales de un biomarcador
BRPI0820793A2 (pt) 2007-12-10 2015-06-16 Hoffmann La Roche Seprase como marcador de câncer
US8592925B2 (en) 2008-01-11 2013-11-26 Seiko Epson Corporation Functional device with functional structure of a microelectromechanical system disposed in a cavity of a substrate, and manufacturing method thereof
WO2009107384A1 (ja) 2008-02-29 2009-09-03 国立大学法人名古屋大学 急性腎障害及び予後推定用バイオマーカー並びにその用途
US20090298106A1 (en) 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
US7998744B2 (en) 2008-07-28 2011-08-16 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
WO2010022210A2 (en) 2008-08-21 2010-02-25 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
NZ610356A (en) 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010025434A1 (en) 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
CN104399089B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2767833A3 (en) 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592488A (en) 2008-11-10 2012-10-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010091236A1 (en) 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and failure
JP2012522491A (ja) 2009-04-03 2012-09-27 ベジニクス ピーティーワイ リミテッド 抗ｖｅｇｆ−ｄ抗体
US8313949B2 (en) * 2009-04-16 2012-11-20 Nextcea Inc. Detecting phospholipidosis and diagnosing lysosomal storage disorders
WO2010128158A1 (en) 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
US8974491B2 (en) 2009-06-23 2015-03-10 Infarct Reduction Technologies Inc. Methods for adaptive limb occlusion
AU2010279302B2 (en) 2009-08-07 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011017680A1 (en) 2009-08-07 2011-02-10 Rules-Based Medicine,Inc Computer methods and devices for detecting kidney damage
CN102792161B (zh) * 2009-08-28 2014-11-12 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后的方法及组合物
WO2011035323A1 (en) * 2009-09-21 2011-03-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
JP2013519095A (ja) 2010-02-05 2013-05-23 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
KR20140051754A (ko) 2010-02-26 2014-05-02 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
US20120329071A1 (en) 2010-03-05 2012-12-27 Mark Chance Protein biomarkers and therapeutic targets for renal disorders
US20130210043A1 (en) 2010-06-23 2013-08-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130035290A1 (en) 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury
WO2013006629A1 (en) 2011-07-06 2013-01-10 Alere San Diego Inc. Methods and compositions for assigning likelihood of acute kidney injury progression
US9459261B2 (en) 2011-08-26 2016-10-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
CN105051542A (zh) * 2012-10-31 2015-11-11 阿斯图德医疗有限公司 定量的侧向流测定法
AU2014207509B2 (en) * 2013-01-17 2019-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
TWI558403B (zh) 2013-06-04 2016-11-21 中央研究院 富含半乳糖脂之植物萃取物及其用途
WO2014197729A1 (en) 2013-06-05 2014-12-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2920521A1 (en) 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
CN105793439B (zh) 2013-11-06 2020-09-04 阿斯图特医药公司 以生物样品进行的针对igfbp7的具有改进的性能的测定
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN108139409B (zh) 2015-10-08 2020-07-24 豪夫迈·罗氏有限公司 当在外科手术之前测量时用于预测aki的风险的igfbp7
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
WO2018081578A1 (en) 2016-10-28 2018-05-03 Astute Medical, Inc. Use of antibodies to timp-2 for the improvement of renal function
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
JP7315466B2 (ja) 2017-04-05 2023-07-26 アスチュート メディカル，インコーポレイテッド 生体試料中において改善した性能を有する、ｔｉｍｐ２に関するアッセイ
JP2020519904A (ja) 2017-05-07 2020-07-02 アスチュート メディカル，インコーポレイテッド 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用

Also Published As

Publication number Publication date
JP2016505143A (ja) 2016-02-18
WO2014113558A1 (en) 2014-07-24
HK1253858A1 (zh) 2019-07-05
CN105074466A (zh) 2015-11-18
US20150355196A1 (en) 2015-12-10
US9360488B2 (en) 2016-06-07
PL2946211T3 (pl) 2018-08-31
CN107976547B (zh) 2020-08-25
EP2946211A1 (en) 2015-11-25
AU2020201732A1 (en) 2020-03-26
EP3361255B1 (en) 2020-03-11
JP6681195B2 (ja) 2020-04-15
JP2020112568A (ja) 2020-07-27
US20160274128A1 (en) 2016-09-22
AU2014207509B2 (en) 2019-12-12
US20170307634A1 (en) 2017-10-26
EP3734280B8 (en) 2022-08-24
EP3734280B1 (en) 2022-06-01
PT2946211T (pt) 2018-06-04
CA2898581C (en) 2022-07-05
EP2946211B1 (en) 2018-02-28
TR201807542T4 (tr) 2018-06-21
CN105074466B (zh) 2018-01-09
CA3158996A1 (en) 2014-07-24
EP3734280A2 (en) 2020-11-04
EP3361255A1 (en) 2018-08-15
CA2898581A1 (en) 2014-07-24
EP3734280A3 (en) 2021-01-20
US20230008880A1 (en) 2023-01-12
AU2014207509A1 (en) 2015-08-20
ES2926197T3 (es) 2022-10-24
US9696322B2 (en) 2017-07-04
ES2681955T3 (es) 2018-09-17
CN107976547A (zh) 2018-05-01
EP4105657A1 (en) 2022-12-21
EP2946211A4 (en) 2016-11-02
US11099194B2 (en) 2021-08-24

Similar Documents

Publication Publication Date Title
HK1253858A1 (zh) 用於腎損傷和腎衰竭的診斷及預後的方法和組合物
HK1222455A1 (zh) 用於腎損傷和腎衰竭的診斷及預後的方法和組合物
EP3077819A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT2748605T (pt) Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
EP2788759A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING KIDNEY INJURY AND RENAL FAILURE
EP2531620A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
EP3281011A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2988770A4 (en) COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
GB201303936D0 (en) Methods and Compositions for the Diagnosis of Alzheimers Disease
EP2721404A4 (en) DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
EP2834638A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF A SEPSIS
PT3210018T (pt) Métodos e composições para o diagnóstico e prognóstico de lesão renal e insuficiência renal
IL245602A0 (en) Compositions and methods for evaluating intestinal function
EP2729803A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL FAILURE
EP2661626A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
EP2531622A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
EP2783213A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
HK1204339A1 (zh) 用於腎損傷和腎衰竭的診斷及預後的方法和組合物
EP3218724A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2531621A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
EP3068893A4 (en) Methods and compositions for diagnosis and prognosis of sepsis
EP2962109A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
HK1207155A1 (zh) 用於腎損傷和腎衰竭的診斷及預後的方法和組合物
EP2875347A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF SEPSIS
HK1203620A1 (zh) 用於腎損傷和腎衰竭的診斷及預後的方法和組合物